NorthView Acquisition Stock (NASDAQ: NVAC)

Latest news for NorthView Acquisition (NASDAQ:NVAC) Stock

NorthView Acquisition Corp is a newly organized blank check company.

NorthView Acquisition Corporation - Common Stock

NorthView Acquisition Corp

Nova Cannabis Inc

NorthView Acquisition Corporation - Rights

NorthView Acquisition Corporation - Warrant

<p>JP Morgan  analyst Matthew Boss   maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Overweight and raises the price target from $284 to $288.</p>


News

Price Target

Analyst Ratings

BURL

JP Morgan Maintains Overweight on Burlington Stores, Raises Price Target to $288

<p>RBC Capital  analyst Keith Mackey   maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Outperform and lowers the price target from $45 to $44.</p>


RBC Capital Maintains Outperform on Halliburton, Lowers Price Target to $44

<p>BWS Financial  analyst Hamed Khorsand   initiates coverage on Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Sell rating and announces Price Target of $10.</p>


Initiation

BWS Financial Initiates Coverage On Symbotic with Sell Rating, Announces Price Target of $10

<p>RBC Capital  analyst Jon Arfstrom   maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and raises the price target from $16 to $17.</p>


HBAN

RBC Capital Maintains Outperform on Huntington Bancshares, Raises Price Target to $17

<p>BMO Capital  analyst James Thalacker   maintains WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Market Perform and lowers the price target from $90 to $87.</p>


BMO Capital Maintains Market Perform on WEC Energy Group, Lowers Price Target to $87

Legal

American Electric Power Says On July 10 Court Preliminarily Approved Co's Settlement With Four Shareholders; Settlement Includes Implementation Of Certain Corporate Governance Changes

Contracts

Embraer-Empresa Brasileira De Aeronautica

Embraer Signs Contract With Austria, The Netherlands For Firm Order For Nine C-390 Millennium Aircraft; Embraer Says Contract Includes Five Aircraft To The Netherlands, Four To Austria; Deliveries Expected To Start In 2027 And Conclude By 2030; Defense Head Says Expects To Produce 12 C-390 Aircraft Per Year By 2030, Up From Four This Year; Supply Chain A Challenge

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Robinhood Markets</strong>.</p>
<p>Looking at options history for Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 36% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $105,500 and 8, calls, for a total amount of $248,418.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.0 to $25.5 for Robinhood Markets over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Robinhood Markets options trades today is 14958.1 with a total volume of 2,230.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Robinhood Markets's big money trades within a strike price range of $12.0 to $25.5 over the last 30 days.</p>
<h3>Robinhood Markets Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656900_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$0.46</td>
<td>$0.21</td>
<td>$0.21</td>
<td>$21.50</td>
<td>$42.2K</td>
<td>704</td>
<td>0</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$0.29</td>
<td>$0.27</td>
<td>$0.29</td>
<td>$25.50</td>
<td>$36.8K</td>
<td>1.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/26/24</td>
<td>$0.29</td>
<td>$0.28</td>
<td>$0.29</td>
<td>$25.50</td>
<td>$34.0K</td>
<td>1.8K</td>
<td>56</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$1.12</td>
<td>$1.1</td>
<td>$1.11</td>
<td>$20.00</td>
<td>$33.3K</td>
<td>4.1K</td>
<td>202</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.4</td>
<td>$9.25</td>
<td>$9.4</td>
<td>$20.00</td>
<td>$32.7K</td>
<td>30.4K</td>
<td>60</td>
</tr>
</tbody>
</table>
</p>
<h3>About Robinhood Markets</h3>
<p>Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.</p>
<h3>Current Position of Robinhood Markets</h3>
<ul>
<li>With a trading volume of 2,782,031, the price of HOOD is up by 1.24%, reaching $23.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Robinhood Markets</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $23.0.</p>
<ul>
<li>An analyst from Goldman Sachs persists with their Neutral rating on Robinhood Markets, maintaining a target price of $21. </li>
<li>Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Robinhood Markets, targeting a price of $20. </li>
<li>An analyst from Wolfe Research has elevated its stance to Outperform, setting a new price target at $29. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Underweight rating for Robinhood Markets, targeting a price of $20. </li>
<li>An analyst from Keybanc persists with their Overweight rating on Robinhood Markets, maintaining a target price of $25. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Robinhood Markets options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

HOOD

Looking At Robinhood Markets's Recent Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in INTC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Intel. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 56% bearish. Among these notable options, 6 are puts, totaling $459,954, and 10 are calls, amounting to $597,385.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $24.0 to $75.0 for Intel over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Intel options trades today is 3126.5 with a total volume of 1,446.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Intel's big money trades within a strike price range of $24.0 to $75.0 over the last 30 days.</p>
<h3>Intel Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656895_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/23/24</td>
<td>$1.5</td>
<td>$1.46</td>
<td>$1.5</td>
<td>$34.00</td>
<td>$210.0K</td>
<td>1.8K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.9</td>
<td>$41.00</td>
<td>$195.8K</td>
<td>670</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.9</td>
<td>$41.00</td>
<td>$71.2K</td>
<td>670</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$3.65</td>
<td>$3.55</td>
<td>$3.65</td>
<td>$30.00</td>
<td>$63.8K</td>
<td>769</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$41.00</td>
<td>$59.9K</td>
<td>670</td>
<td style="text-align: right;">300</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intel</h3>
<p>Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.</p>
<p>Following our analysis of the options activities associated with Intel, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Intel Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,648,916, the price of INTC is down by -0.36%, reaching $32.86.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 10 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Intel</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $40.0.</p>
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $40. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intel options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


INTC

Intel's Options: A Look at What the Big Money is Thinking

Kellanova Expands Partnership With Interpublic Group To Accelerate Global Brand Portfolio Growth And Support Ambition To Become A Snacking Powerhouse

<p>Financial giants have made a conspicuous bearish move on MicroStrategy. Our analysis of options history for MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) revealed 57 unusual trades.</p>
<p>Delving into the details, we found 40% of traders were bullish, while 43% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $432,206, and 48 were calls, valued at $3,455,949.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $800.0 to $3800.0 for MicroStrategy over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in MicroStrategy's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to MicroStrategy's substantial trades, within a strike price spectrum from $800.0 to $3800.0 over the preceding 30 days.</p>
<h3>MicroStrategy 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656890_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$351.3</td>
<td>$338.65</td>
<td>$345.05</td>
<td>$1500.00</td>
<td>$241.5K</td>
<td>595</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/26/24</td>
<td>$30.5</td>
<td>$29.65</td>
<td>$29.83</td>
<td>$2000.00</td>
<td>$207.7K</td>
<td>1.2K</td>
<td style="text-align: right;">699</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$70.0</td>
<td>$65.0</td>
<td>$70.0</td>
<td>$2000.00</td>
<td>$140.0K</td>
<td>809</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$596.9</td>
<td>$580.2</td>
<td>$580.2</td>
<td>$1640.00</td>
<td>$116.0K</td>
<td>43</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$121.6</td>
<td>$109.05</td>
<td>$115.0</td>
<td>$2000.00</td>
<td>$115.0K</td>
<td>1.0K</td>
<td style="text-align: right;">26</td>
</tr>
</tbody>
</table>
</p>
<h3>About MicroStrategy</h3>
<p>MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.</p>
<p>In light of the recent options history for MicroStrategy, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is MicroStrategy Standing Right Now?</h3>
<ul>
<li>With a trading volume of 305,500, the price of MSTR is down by -0.66%, reaching $1766.8.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 10 days from now.</li>
</ul>
<h3>What Analysts Are Saying About MicroStrategy</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $1830.5.</p>
<ul>
<li>An analyst from Maxim Group downgraded its action to Buy with a price target of $1835. </li>
<li>Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for MicroStrategy, targeting a price of $1826. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for MicroStrategy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


MSTR

Spotlight on MicroStrategy: Analyzing the Surge in Options Activity

<p>Throughout the last three months, 9 analysts have evaluated EastGroup Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $182.67, along with a high estimate of $208.00 and a low estimate of $172.00. Highlighting a 3.63% decrease, the current average has fallen from the previous average price target of $189.56. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656877_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of EastGroup Props by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$172.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$183.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Todd Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$178.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EastGroup Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of EastGroup Props compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into EastGroup Props's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EGP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on EastGroup Props analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind EastGroup Props</h2>
<p>EastGroup Properties Inc is an equity real estate investment trust. It is engaged in the development, acquisition, and operation of industrial properties in Sunbelt markets throughout the United States, predominantly in the states of Florida, Texas, Arizona, California, and North Carolina. The company manages a portfolio of industrial properties. The vast majority of these properties are multi-tenant business distribution buildings that provide large warehousing and office space for customers. The company derives its revenue in the form of rental income.</p>
<h3>EastGroup Props: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> EastGroup Props's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>14.22%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> EastGroup Props's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>38.03%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> EastGroup Props's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>2.23%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.29%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> EastGroup Props's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.64</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: EastGroup Props In The Eyes Of 9 Experts

<p>During the last three months, 10 analysts shared their evaluations of Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Bloom Energy, revealing an average target of $14.6, a high estimate of $21.00, and a low estimate of $9.00. Surpassing the previous average price target of $13.50, the current average has increased by 8.15%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656859_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Bloom Energy is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Gregory Lewis</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$13.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bloom Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bloom Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Bloom Energy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bloom Energy's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bloom Energy analyst ratings.</strong></a></p>
<h2>Discovering Bloom Energy: A Closer Look</h2>
<p>Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and South Korea.</p>
<h3>Financial Insights: Bloom Energy</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Bloom Energy faced challenges, resulting in a decline of approximately <strong>-14.5%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-24.45%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-11.88%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Bloom Energy's ROA excels beyond industry benchmarks, reaching <strong>-2.45%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Bloom Energy's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>3.11</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Bloom Energy: Insights From 10 Financial Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $341.43, a high estimate of $375.00, and a low estimate of $300.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.51%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656852_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Align Tech is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$325.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$370.00</td>
<td>$333.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Align Tech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Align Tech compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Align Tech's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Align Tech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALGN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Align Tech analyst ratings.</strong></a></p>
<h2>About Align Tech</h2>
<p>Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.</p>
<h3>Key Indicators: Align Tech's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Align Tech's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>5.76%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Align Tech's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.53%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.84%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Align Tech's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.72%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Align Tech's debt-to-equity ratio is below the industry average. With a ratio of <b>0.03</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALGN

Decoding 7 Analyst Evaluations For Align Tech

<p>Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $81.5, a high estimate of $87.00, and a low estimate of $70.00. A decline of 1.81% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656840_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Arcellx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcellx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcellx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Arcellx's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Arcellx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ACLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Arcellx analyst ratings.</strong></a></p>
<h2>Delving into Arcellx's Background</h2>
<p>Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.</p>
<h3>Unraveling the Financial Story of Arcellx</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Arcellx displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>119.16%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-18.34%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Arcellx's ROE excels beyond industry benchmarks, reaching <strong>-1.47%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Arcellx's ROA excels beyond industry benchmarks, reaching <strong>-0.9%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.18</strong>, Arcellx adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ACLX

Decoding 8 Analyst Evaluations For Arcellx

<p>Analysts' ratings for Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.0, a high estimate of $39.00, and a low estimate of $32.00. Marking an increase of 8.53%, the current average surpasses the previous average price target of $32.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656832_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Ameresco. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>William Grippin</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ameresco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ameresco compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Ameresco's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ameresco's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMRC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ameresco analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Ameresco's Background</h2>
<p>Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of revenue from the U.S. Regions segment.</p>
<h3>Unraveling the Financial Story of Ameresco</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ameresco's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>10.1%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-0.99%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ameresco's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.33%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ameresco's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.08%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.79</strong>, Ameresco faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AMRC

Key Takeaways From Ameresco Analyst Ratings

<p>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 21.75% on an annualized basis producing an average annual return of 34.64%. Currently, Krystal Biotech has a market capitalization of $5.82 billion. </p>
<p><strong>Buying $100 In KRYS:</strong> If an investor had bought $100 of KRYS stock 5 years ago, it would be worth <strong>$426.51</strong> today based on a price of $203.66 for KRYS at the time of writing.</p>
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656823_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

KRYS

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

<p>Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has outperformed the market over the past 10 years by 24.75% on an annualized basis producing an average annual return of 35.64%. Currently, Arista Networks has a market capitalization of $105.54 billion. </p>
<p><strong>Buying $100 In ANET:</strong> If an investor had bought $100 of ANET stock 10 years ago, it would be worth <strong>$2,123.20</strong> today based on a price of $336.80 for ANET at the time of writing.</p>
<h3>Arista Networks's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656818_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ANET

$100 Invested In Arista Networks 10 Years Ago Would Be Worth This Much Today

<p>Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $24.00, and a low estimate of $21.00. This upward trend is evident, with the current average reflecting a 4.84% increase from the previous average price target of $20.67.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721656810_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Regions Finl by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kenneth Usdin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regions Finl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regions Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Regions Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Regions Finl analyst ratings.</strong></a></p>
<h2>All You Need to Know About Regions Finl</h2>
<p>Regions Financial is a regional bank headquartered in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.</p>
<h3>Regions Finl: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Regions Finl faced challenges, resulting in a decline of approximately <strong>-10.46%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Regions Finl's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>19.63%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Regions Finl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.2%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Regions Finl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Regions Finl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.28</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Have This To Say About Regions Finl

Politics

General

Illinois Governor J.B. Pritzker Endorses Harris For President

NorthView Acquisition Corp. (NVAC) has shared an announcement. At NorthView Acquisition Corporation's 2024 Annual Meeting, a commanding 93.64% of s...

NorthView Acquisition Corp. Shareholders Approve Key Decisions

NorthView Acquisition Corporation announces receipt of notice from Nasdaq

NVAC

Press Releases

NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of Annual Report on Form 10-Q

NVACR

NorthView Acquisition

<p>NorthView Acquisition Corporation. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAC#NASDAQ">NVAC</a>) (the "Company") announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended March 31, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").</p>

NorthView Acquisition Announces Receipt From Nasdaq Regarding Filing oO Annual Report On Form 10-Q

On April 20, Northview Acquisition Corp Got Notice From Nasdaq Indicating Co No Longer Complies With Nasdaq Listing Rule

<p>Profusa, Inc. (&ldquo;Profusa&rdquo;), a digital health company that is pioneering the next generation of personalized medicine and NorthView Acquisition Corp. &ldquo;NorthView&rdquo;) (Nasdaq:&nbsp;NVAC), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the &ldquo;Business Combination Agreement&rdquo;) on&nbsp;November 7, 2022&nbsp;that will result in Profusa becoming a publicly listed company.</p>

<p>Upon closing of the transaction, NorthView will be renamed &ldquo;Profusa Inc.&rdquo; (the &ldquo;Combined Company&rdquo;).</p>

<p>Profusa is based in Emeryville, CA and is a digital health company that is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors. Profusa&rsquo;s technology addresses the human body&rsquo;s response to the presence of foreign material, enabling long-term monitoring of various biochemical parameters in real-time, with months of functionality, at a fraction of the cost of current solutions. Profusa&rsquo;s novel approach, that has been in development for approximately nine years, is intended to be the foundational platform of bioengineered sensors supporting real time biochemical monitoring, enabling a real-time stream of data for a wide-ranging set of applications, including wound care and continuous glucose monitoring for diabetes management. Profusa&rsquo;s technology enables continuous transmission of wireless and cloud based actionable medical-grade data for personal, professional and medical use.</p>

<p><strong>Profusa&rsquo;s</strong>&nbsp;<strong>Chairman</strong>&nbsp;<strong>and CEO,&nbsp;Ben Hwang,&nbsp;PhD&nbsp;and the current management team will continue to lead the Combined Company.</strong></p>

<p>Ben Hwang of Profusa noted, &ldquo;We are excited to partner with NorthView to accelerate our growth and bring our solution to those in need, creating a true enabling technology that provides a data-driven, user-based, real-time health decision solution.&rdquo;</p>

<p>Profusa&rsquo;s mission is to make our body&rsquo;s chemistry easily accessible to improve health and wellness, becoming the leader in the development of real-time biosensors that provide unprecedented data-driven insights into our overall health status. Smaller than the width of a few hairs, each biosensor is a flexible hydrogel fiber of approximately 3 mm in length and less than half a millimeter&nbsp;wide, it is easily injected under the skin for ease of deployment and long-term functionality. The hydrogel fiber is linked to light-emitting fluorescent molecules that continuously signal in&nbsp;proportion to the concentration of a body chemical, such as oxygen, glucose, or other biomolecules&nbsp;of interest. Unlike conventional sensors, such as those found in other continuous glucose monitors, this novel approach allows the Profusa sensing platform to deliver accurate data, with months of functionality per injection, at a cost that enables broad user adoption.</p>

<p>Profusa&rsquo;s first product offering, currently &nbsp;registered under CE Mark in the European Union, the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=zELT2q4Ij9pFyKGL5u3ExOSHSo7yrSQh2rQu5f1LN50Hy72d9tj-vZpI-vfuJksMMzhzNyAcFQb2CErOCRR0CVgcsr0-8sEWIAd0NwyscDg=" target="_blank"><em>Lumee&trade; Oxygen Platform</em></a>, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The&nbsp;<em>Lumee&trade; Oxygen Platform</em>&nbsp;has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Profusa&rsquo;s second offering is in clinical development for continuous glucose monitoring (CGM). The global CGM market size is&nbsp;expected to grow from $6.13 billion in 2021 to $16.33 billion by 2030 at CAGR of 17.33% according to Strategic Market Research due principally to the rising incidence of diabetes, new product launches and government initiatives.</p>

<p>Jack Stover, CEO of NorthView<strong>,&nbsp;</strong>commented: &ldquo;We believe our merger with Profusa represents a rare opportunity to partner with a management team and business that is highly sought after to be a public company with a true platform solution, globally focused and with technology validated via product approval and ready for launch. We are confident that this business combination will provide Profusa or the Combined Company with the financial resources to launch its commercial plans for its oxygen biosensor product, seek FDA approval for its continuous glucose monitoring product and continue to develop near term revenue opportunities to leverage its novel tissue integrated biosensor technology platform.&rdquo; &nbsp;</p>

<p><strong>Transaction Overview</strong></p>

<p>The pro forma equity valuation of the Combined Company is expected to be approximately $264 million assuming 80% redemptions or approximately $416 million assuming no redemptions. Estimated cash proceeds to the Combined Company from the transaction are expected to consist of NorthView&rsquo;s approximately&nbsp;$39 million of cash in trust assuming 80% redemptions or approximately $193 million assuming no redemptions.</p>

<p>Upon the closing of the transaction, and assuming 80% of NorthView&rsquo;s public stockholders elect to redeem their shares of common stock and no additional shares of common stock are issued upon the closing of the transaction, it is anticipated that NorthView&rsquo;s public stockholders would retain an ownership interest of approximately 21.6% in the Combined Company, the sponsors, officers, directors and other holders of NorthView founder shares will retain an ownership interest of approximately 19.7% of the Combined Company, and the Profusa stockholders will own approximately 58.7% of the Combined Company.</p>

<p>Alternatively, assuming no redemptions by NorthView&rsquo;s public stockholders and no additional shares of common stock are issued upon the closing of the transaction, it is anticipated that NorthView&rsquo;s public stockholders would retain an ownership interest of approximately 50.2% in the Combined Company, the sponsors, officers, directors and other holders of NorthView founder shares will retain an ownership interest of approximately 12.5% of the Combined Company, and the Profusa stockholders will own approximately 37.3% of the Combined Company.</p>

<p>The board of directors of each of NorthView and Profusa has approved the transaction. NorthView, Profusa and certain stockholders of Profusa (the &ldquo;Key Profusa Stockholders&rdquo;) have entered into support agreements pursuant to which such Key Profusa Stockholders agreed to, among other things, within five (5) business days after the proxy statement/prospectus relating to the approval by NorthView shareholders of the transaction is declared effective by the Securities and Exchange Commission and delivered or otherwise made available to NorthView shareholders, execute and deliver a written consent with respect to the outstanding shares of Profusa common stock and preferred stock held by the Key Profusa Stockholders adopting the Business Combiantion Agreement and related transactions. The shares of Profusa common stock and preferred stock that are owned by the Key Profusa Stockholders and subject to such support agreements represent a majority of the outstanding voting power of Profusa common stock and preferred stock (on an as converted basis). The transaction will require the approval of the stockholders of Profusa and NorthView and is subject to other customary closing conditions including the receipt of certain regulatory approvals.</p>

<p>Additional information about the proposed transaction, including a copy of the business combination, will be provided in a Current Report on Form 8-K to be filed by NorthView with the SEC and available at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=6Wl7sCKiyyLHKAI5zE964A7uHlGXOzpyREeu-yWKO8dgvnic6ZufoEa_NHt8VER0El5NKIDzWCmcOba-lauYgg==" target="_blank">www.sec.gov</a>.</p>

<p>Advisors</p>

<p>I-Bankers Securities&nbsp;Inc. and Dawson James Securities, Inc. acted as financial advisors to NorthView. H.C. Wainwright &amp; Co. acted as financial advisor to Profusa. ArentFox Schiff LLP acted as legal advisor to NorthView and Sidley Austin LLP acted as legal advisor to Profusa.</p>

Profusa, Inc. To Become A Publicly Traded Company Via Merger With Northview Acquisition Corp

<p>&nbsp;</p>

<h1>&nbsp;</h1>

<p>Friday&#39;s session saw 10 companies set new 52-week highs.</p>

<h2>Interesting Highlights From Today&#39;s 52-Week Highs:</h2>

<ul>
	<li>The largest company by market cap to set a new 52-week high was <strong>Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>)</strong>.</li>
	<li><strong>California Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALB#NASDAQ">CALB</a>)</strong> was the smallest firm based on market cap to set a new 52-week high.</li>
	<li><strong>Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>)</strong> was the biggest winner, trading up 4.61% to reach its 52-week high.</li>
	<li><strong>California Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALB#NASDAQ">CALB</a>)</strong> saw the sharpest decline, as it traded 0.0% after setting a new 52-week high.</li>
</ul>

<p>The stocks that set new 52-week highs on Friday are the following:</p>

<ul>
	<li><strong>Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>)</strong> shares achieved a new 52-week high on Friday morning, hitting $14.06 with a daily change of up 0.98%.</li>
	<li><strong>Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>)</strong> shares achieved a new 52-week high on Friday morning, hitting $75.48 with a daily change of up 1.23%.</li>
	<li><strong>NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>)</strong> shares reached a new 52-week high of $28.66 on Friday morning, moving up 2.11%.</li>
	<li><strong>Sonder Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>)</strong> stock set a new 52-week high of $9.86 Friday morning. Over the session, the stock traded down 1.07%.</li>
	<li><strong>Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>)</strong> shares were up 4.61% on Friday morning to hit a new 52-week high of $90.05.</li>
	<li><strong>Bullpen Parlay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPAC#NASDAQ">BPAC</a>)</strong> stock hit a yearly high price of $10.00. The stock was up 2.04% for the day.</li>
	<li><strong>BCB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCBP#NASDAQ">BCBP</a>)</strong> shares broke to $16.45 on Friday, setting a new 52-week high with a change of down 0.12%.</li>
	<li><strong>NorthView Acquisition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAC#NASDAQ">NVAC</a>)</strong> shares set a new yearly high of $9.76 this morning. The stock was up 0.21% on the session.</li>
	<li><strong>First Northwest Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNWB#NASDAQ">FNWB</a>)</strong> stock made a new 52-week high of $20.85 Friday. The stock was up 0.48% for the day.</li>
	<li><strong>California Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALB#NASDAQ">CALB</a>)</strong> stock on Friday broke to a yearly high of $22.94. Shares traded 0.0% (flat).</li>
</ul>

<p><a href="https://www.benzinga.com/trading-ideas/long-ideas/22/01/25155940/4-penny-stocks-insiders-are-buying-cymabay-therapeutics-avalo-therapeutics-and-more"><em>Have a look at insider trading in penny stocks </em></a></p>

<p>&nbsp;</p>

<p>&nbsp;</p>

<p><em>Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. <a href="https://pro.benzinga.com/?afmc=2a&amp;utm_source=benzinga.com&amp;utm_medium=web&amp;utm_campaign=premium_products">Click here to learn more</a>.</em></p>


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

NorthView Acquisition

News

Latest news for NorthView Acquisition (NASDAQ:NVAC) Stock

Friday, June 07, 2024

Wednesday, April 26, 2023

Monday, November 07, 2022

Friday, January 28, 2022